Axsome Therapeutics, Inc.’s Post

#MOUD #opioidusedisorder #opioidcrisis #opioidepidemic #physician #residents Residents, fellows, and attendings in IM, FM, EM, peds, psych, and Ob/Gyn: we want to hear your input on challenges to pharmacologic treatment of opioid use disorder! Please fill out this short survey:

Well, being on the news has been bad for posting on LinkedIn (lack of time) but great for business! Since the news story ran one week ago I have met with 8 new clients at The Deprescribing Clinic, lots more appointments booked, plus 2 speaking engagements! Whew! Anxiety and depression are rampant. Our primary providers are managing many patients the best they can but there is not enough psychiatrists and counselors…typically at least a 3 month wait or not accepting new patients. Not only that the expense to patients… But I have a very interesting case I cannot wait to tell you about! #pharmacogenomics #mentalhealth #pharmacist

New Post: Diagnostic value and role of serum miR-15a-5p in patients with schizophrenia

CSWE is facilitating a six-part webinar series funded by Providers Clinical Support System–Medication for Opioid Use Disorder (PCSS-MOUD). This webinar series invites us to merge results from cutting edge research and clinical experience to inform social work practice. We will explore how social work practitioners have implemented research findings in their practice, how people with substance use disorders (SUD) are experiencing services, and what are the pressing gaps that need to be addressed. Join us for the third webinar on Thursday, May 16, 2024, from 1:00–2:00 PM (ET), “Advancing Women's Substance Use Disorder Treatment through Community-Based Research Partnerships.” Throughout this webinar, attendees will be introduced to the foundational aspects of creating and sustaining productive community-based research partnerships. We will highlight successful case studies and models that demonstrate the practical application of these collaborations, showcasing how they can lead to the development of innovative, evidence-based treatment strategies specifically tailored for women. Learn more and register here. LINK: https://ow.ly/XceA50RzQSY

In this pilot study, we aimed to compare the acceptability, feasibility, and effectiveness of online vs. face-to-face Cognitive Behavioral Therapy as a treatment for pediatric OCD. https://buff.ly/3ANldZb

In a paper from the 60th Journal Conference, Yohannes provides a detailed review of psychosocial support in PR including gaps in knowledge related to the effects of cognitive behavioral therapy (CBT) and antidepressant drug therapy on psychosocial factors in patients with COPD. https://lnkd.in/enWhCU-g

Clinical characteristics of seizure recurrence and epilepsy development in patients with alcohol-related seizures https://lnkd.in/gTaMV6nk

In recent years, Zellweger Syndrome has become known as Zellweger Spectrum Disorder (ZSD) to better reflect the range of severity and clinical manifestations observed in patients with this condition. The term "Zellweger Spectrum Disorder" provides a more accurate and encompassing description of the range of clinical presentations associated with peroxisomal disorders, and we encourage physicians, scientists, GFPD Warriors, and families to utilize this inclusive language. #GFPD #PBDZSD #RareDiseaseAwareness #RareDisease #FindACure #GFPDisFamily #GFPDisResearch #GFPDisHope #ZellwegerSyndrome #ZellwegerSpectrumDisorder #PeroxisomalDisorder #MedicallyComplexKids #DBPD #AMACRD #ACOX

In this pilot study, we aimed to compare the acceptability, feasibility, and effectiveness of online vs. face-to-face Cognitive Behavioral Therapy as a treatment for pediatric OCD. https://buff.ly/3ANldZb

For newcomers to clinical research, it can be difficult to break into specialties like CNS or neurodegenerative clinical trials.  Kelley Yokum MD describes how it takes time and perseverance to establish (and invent!) your role. As an industry, welcoming new talent will bring fresh perspectives and new approaches. We need to open our eyes and consider training (and accepting) newcomers in order to solve some of the problems we are facing. ➡️Dr. Kelley Yokum is the Principal Investigator and Co-Owner of K2 Medical Research in Tampa, Florida. Dr. Yokum is a board-certified psychiatrist who oversees clinical trials in schizophrenia, Alzheimer’s disease, anxiety, depression, and memory loss, among others. #clinicaltrials #entrepreneur #clinicalresearch #ichorclinical #perseverance #womeninresearch